{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:12:03Z","timestamp":1792685523863,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012544","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Executive Yuan Republic of China Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218349","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:15:19Z","timestamp":1771978519000},"page":"218349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting PCK1 to overcome CDK4\/6 inhibitor resistance for breast cancer therapy"],"prefix":"10.1016","volume":"645","author":[{"given":"Chen-Shiou","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieu-Thanh","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-1051","authenticated-orcid":false,"given":"Yi-Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1669-0037","authenticated-orcid":false,"given":"Wei-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7905-580X","authenticated-orcid":false,"given":"Ling-Chu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciao-Ling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Chih-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S. Clifford","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-4740","authenticated-orcid":false,"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218349_bib1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218349_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218349_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218349_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","article-title":"CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment","volume":"21","author":"DeMichele","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218349_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218349_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors' current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218349_bib8","article-title":"CDK4\/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218349_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218349_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218349_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1148792","article-title":"CDK4\/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective","volume":"11","author":"Zhou","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2026.218349_bib12","article-title":"CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218349_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217356","article-title":"TFAP2C-DDR1 axis regulates resistance to CDK4\/6 inhibitor in breast cancer","volume":"610","author":"Mughal","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218349_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216747","article-title":"CD63(+) cancer-associated fibroblasts confer CDK4\/6 inhibitor resistance to breast cancer cells by exosomal miR-20","volume":"588","author":"Sun","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218349_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216968","article-title":"EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer","volume":"593","author":"Belli","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218349_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"Alvarez-Fernandez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218349_bib18","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1016\/j.molcel.2021.08.031","article-title":"Moonlighting functions of metabolic enzymes and metabolites in cancer","volume":"81","author":"Pan","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217441","article-title":"Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer","volume":"611","author":"Hindes","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218349_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218349_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217156","article-title":"Glycolysis, the sweet appetite of the tumor microenvironment","volume":"600","author":"Kooshan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218349_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbcan.2019.05.006","article-title":"Gluconeogenesis in cancer cells - repurposing of a starvation-induced metabolic pathway?","volume":"1872","author":"Grasmann","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218349_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41420-024-02240-8","article-title":"PCK1 as a target for cancer therapy: from metabolic reprogramming to immune microenvironment remodeling","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218349_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-020-2183-2","article-title":"The gluconeogenic enzyme PCK1 phosphorylates INSIG1\/2 for lipogenesis","volume":"580","author":"Xu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218349_bib26","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41388-017-0070-6","article-title":"Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218349_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.molcel.2015.09.025","article-title":"PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth","volume":"60","author":"Montal","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41419-021-04201-w","article-title":"Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer","volume":"12","author":"Zhu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218349_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020462","article-title":"Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer","volume":"12","author":"Huang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218349_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.csbj.2021.12.028","article-title":"Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning","volume":"20","author":"Yang","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.canlet.2026.218349_bib31","first-page":"97","article-title":"Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method","volume":"6","author":"Zhang","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218349_bib32","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.4161\/cc.10.21.18094","article-title":"DNA ligase III: a spotty presence in eukaryotes, but an essential function where tested","volume":"10","author":"Simsek","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2026.218349_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","article-title":"Cyclin D-CDK4\/6 functions in cancer","volume":"148","author":"Gao","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218349_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218349_bib35","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.4161\/15384101.2014.946841","article-title":"The CDK4\/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4\/6 complexes","volume":"13","author":"Paternot","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2026.218349_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41523-022-00494-y","article-title":"Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy","volume":"8","author":"Gharbi","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218349_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218349_bib39","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41467-023-37142-3","article-title":"Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K\/AKT\/PDGF axis activation in male mice","volume":"14","author":"Ye","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218349_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161713","article-title":"Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression","volume":"133","author":"Gou","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218349_bib41","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2147\/OTT.S241717","article-title":"PCK1 regulates glycolysis and tumor progression in clear cell renal cell carcinoma through LDHA","volume":"13","author":"Shi","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2026.218349_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3825760","article-title":"Identification of novel miRNAs, targeting genes, signaling pathway, and the small molecule for overcoming oxaliplatin resistance of metastatic colorectal cancer","volume":"2022","author":"Misbah","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.canlet.2026.218349_bib43","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.3390\/cancers15204936","article-title":"Breast cancer molecular subtypes differentially express gluconeogenic rate-limiting enzymes-obesity as a crucial player","volume":"15","author":"Luis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218349_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168276","article-title":"Mammalian DNA ligases; roles in maintaining genome integrity","volume":"436","author":"Sallmyr","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218349_bib45","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1158\/1078-0432.CCR-17-3702","article-title":"Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers","volume":"24","author":"Anurag","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218349_bib46","first-page":"14","article-title":"Genomic markers of CDK 4\/6 inhibitor resistance in hormone receptor positive metastatic breast cancer","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218349_bib47","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","article-title":"Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization","volume":"12","author":"Diehl","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2026.218349_bib48","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1242\/jcs.01210","article-title":"cAMP-induced degradation of cyclin D3 through association with GSK-3beta","volume":"117","author":"Naderi","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2026.218349_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940939","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer","volume":"12","author":"du Rusquec","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218349_bib50","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-17-0803","article-title":"Combined CDK4\/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms","volume":"23","author":"Olmez","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218349_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11427-021-2140-8","article-title":"Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4\/6 inhibitor in breast cancer that can be reversed by PI3K\/mTOR inhibitors","volume":"66","author":"Cai","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.canlet.2026.218349_bib52","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","article-title":"CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence","volume":"83","author":"Crozier","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib53","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1016\/j.molcel.2023.10.020","article-title":"Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest","volume":"83","author":"Foy","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218349_bib54","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1038\/s41467-024-45835-6","article-title":"Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial","volume":"15","author":"Gomez Tejeda Zanudo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218349_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1555921","article-title":"Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study","volume":"15","author":"Tolaney","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218349_bib56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3350\/cmh.2022.0068","article-title":"Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- kappaB signaling pathways","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218349_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28114380","article-title":"Inhibition of mitochondrial antioxidant defense and CDK4\/6 in Mesothelioma","volume":"28","author":"Kratzke","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2026.218349_bib58","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1021\/acsnano.3c10142","article-title":"Targeted liposomes sensitize plastic melanoma to ferroptosis via senescence induction and coenzyme depletion","volume":"18","author":"Fan","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218349_bib59","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:12:32Z","timestamp":1777551152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":59,"alternative-id":["S0304383526001126"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218349","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PCK1 to overcome CDK4\/6 inhibitor resistance for breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218349"}}